Please check your internet connection and try again.
## Ecospirin (Aspirin) Enteric-Coated
### Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits platelet aggregation. The enteric coating is designed to delay absorption until the drug reaches the small intestine, potentially reducing gastric irritation.
### Primary Indications
* **Cardiovascular Prevention:** To reduce the risk of myocardial infarction, stroke, and cardiovascular death in patients with established cardiovascular disease or risk factors.
* **Analgesia and Antipyresis:** For mild to moderate pain and fever (less common indication for enteric-coated formulations due to slower onset).
### Adult Dosing
* **Cardiovascular Prevention:**
* **Secondary Prevention:** Typically 75-325 mg once daily.
* **Primary Prevention:** Dosing varies based on individual risk assessment; commonly 75-100 mg once daily. Current guidelines often recommend against routine primary prevention in low-risk individuals.
* **Analgesia/Antipyresis:** Doses range from 325 mg to 650 mg every 4-6 hours as needed. Maximum daily dose generally 4000 mg.
### Pediatric Dosing
Aspirin use in children and adolescents is generally **contraindicated** for fever or viral illnesses due to the risk of Reye's syndrome. There are specific indications (e.g., Kawasaki disease) where aspirin may be used under strict medical supervision, but dosing is highly individualized and institution-dependent. Consult pediatric specialty guidelines for these rare indications.
### Dose Adjustments
* **Hepatic Impairment:** Use with caution. Monitor for signs of hepatic toxicity.
* **Renal Impairment:** Use with caution, especially at higher doses. Risk of renal toxicity increases with dose and duration of therapy.
* **Elderly:** Increased risk of gastrointestinal bleeding and other adverse effects. Lower doses may be considered.
### Contraindications
* Hypersensitivity to aspirin, salicylates, NSAIDs, or any component of the formulation.
* Active peptic ulcer disease.
* History of gastrointestinal bleeding or perforation related to previous NSAID therapy.
* Bleeding disorders (e.g., hemophilia, thrombocytopenia).
* Severe hepatic impairment.
* Severe renal impairment.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Third trimester of pregnancy.
### Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, gastritis, peptic ulceration, GI bleeding, perforation.
* **Hematologic:** Increased bleeding time, bruising, epistaxis, hematuria.
* **Hypersensitivity:** Bronchospasm (especially in aspirin-sensitive asthmatics), urticaria, angioedema, rash.
* **Other:** Tinnitus, hearing loss (especially at higher doses), dizziness, headache, renal impairment, Reye's syndrome (in children/adolescents with viral illness).
### Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Increased risk of bleeding.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** Increased risk of bleeding.
* **Methotrexate:** Increased risk of methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Decreased efficacy of uricosuric agents.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, beta-blockers):** NSAIDs can reduce their antihypertensive effect.
* **Alcohol:** Increased risk of GI bleeding.
### Monitoring
* **Signs of GI bleeding:** Melena, hematemesis, abdominal pain.
* **Signs of bleeding:** Easy bruising, prolonged bleeding from cuts, epistaxis.
* **Renal function:** Especially in patients with pre-existing renal disease or those receiving concurrent nephrotoxic agents.
* **Hepatic function:** Particularly with long-term use or higher doses.
* **Tinnitus or hearing changes:** May indicate salicylate toxicity.
### Clinical Pearls
* The enteric coating allows the tablet to pass through the stomach largely intact. It is crucial that these tablets are **swallowed whole** and **not crushed, chewed, or broken**, as this will destroy the enteric coating and increase the risk of gastric irritation.
* For urgent situations requiring rapid platelet inhibition (e.g., acute coronary syndrome), non-enteric-coated aspirin should be used.
* Long-term low-dose aspirin therapy for cardiovascular prevention should be individualized and based on a risk-benefit assessment.
* Always consult the most current prescribing information for the specific product being used, as formulations and recommendations can vary.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace clinical judgment or individual patient assessment. Always verify current prescribing information and consult relevant guidelines before making therapeutic decisions.
